ARTEMIDE-Biliary01

A phase III double blind placebo-controlled study of Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer (BTC) After Resection

ARTEMIDE-Biliary01 is investigating whether giving rilvegostomig (an immunotherapy drug) together with standard chemotherapy, may delay or lower the chance of BTC coming back after surgery as compared to chemotherapy plus placebo. The study is being conducted in patients with biliary tract cancer (cholangiocarcinoma or gallbladder cancer) who are free of disease after surgery. 

Locations
This is a global study which is open and recruiting at several sites across the UK and in Europe (Belgium, Denmark, France, Germany, Italy, Spain, Norway and Poland). 

For latest information on current locations, and for further details on the study, see: NCT06109779

Sponsor email: [email protected]